Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACA...

Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunome (IMNM) and COMPASS Pathways (CMPS) with bul...

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), COMPASS Pathways (CMPS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Immunome (IMNM) with bullish sen...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMNM	$23.08	-0.13%	595.41K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMNM	$23.08	-0.1%	595.41K
3
4
5
6

IMNM

IMNM

Get Immunome Inc. Data in Excel

Get Immunome Inc. Data in Excel